NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

By Ribel U.   Larsen M.O.   Rolin B.   Carr R.D.   Wilken M.   Sturis J.   Westergaard L.   Deacon C.F.   Knudsen L.B.  

European Journal of Pharmacology, Vol. 451, Iss. 2, 2002-09 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Developments of Glucagon Like Peptide-1 (GLP-1) and Long-acting Analogs in Clinical and Preclinical Studies for Treatment of Type 2 Diabetes

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 9, 2013-10 ,pp. : 835-841

Bentham Science Publishers

Access to resources Recommend Favorite

Novel GLP-1 receptor agonists for diabetes

By Garber Alan J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 45-57

Informa Healthcare

Access to resources Recommend Favorite

Influence of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Landiolol Hydrochloride, an Ultra-Short-Acting β 1 -Blocker

By Takahata Takenori   Yasui-Furukori Norio  

Drugs in R&D, Vol. 6, Iss. 6, 2005-01 ,pp. : 385-394

Adis International

Access to resources Recommend Favorite

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue

By Retterstøl Kjetil  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1405-1411

Informa Healthcare

Access to resources Recommend Favorite